IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Phase 1 oncology biotech developing allogeneic gamma-delta T cell therapies.
Industry: Health Care
Latest Trade: $3.15 0.00 (0.0%)
First Day Return: 0.0%
Return from IPO: -68.5%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 10/16/2020 |
Offer Price | $10.00 |
Price Range $10.00 - $12.00 | |
Offer Shares (mm) | 4.0 |
Deal Size ($mm) | $40 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 07/29/2021 |
Offer Price | $10.00 |
Price Range $10.00 - $12.00 | |
Offer Shares (mm) | 4.0 |
Deal Size ($mm) | $40 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
B. Riley Securities |
Company Data | |
---|---|
Headquarters | New York, NY, United States |
Founded | 2016 |
Employees | 7 |
Website www.in8bio.com |